OTCMKTS:STDAF - Stada Arzneimittel Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $94.05 0.00 (0.00 %) (As of 07/22/2018 08:52 AM ET)Previous Close$94.05Today's Range$94.05 - $94.0552-Week Range$64.91 - $108.40VolumeN/AAverage VolumeN/AMarket Capitalization$5.86 billionP/E Ratio27.83Dividend YieldN/ABeta0.94 Company ProfileAnalyst RatingsEarnings HistoryHeadlinesSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email STADA Arzneimittel Aktiengesellschaft engages in the development and marketing of pharmaceutical products for the health care and pharmaceutical markets worldwide. It operates through two segments, Generics and Branded Products. The Generics segment provides various generic active ingredients, including Tilidin Naloxone for pain; Atorvastatin for elevated cholesterol levels; Epoetin zeta for anemia; Diclofenac for pain/inflammation; and Pantoprazole for gastric ulcer/reflux. The Branded Products segment offers APO-Go a Parkinson's medicine; Grippostad a cold medicine; Aqualor for rhinitis/sore throat; Snup for rhinitis; and Vitaprost for prostate disease indications. The company is also involved in the wholesale activities in the pharmaceutical market. It serves patients and consumers, doctors, pharmacies and pharmacy chains, hospitals, mail-order companies, buying groups, wholesalers, and other service providers in the health care market, as well as public or private health insurance organizations. The company was founded in 1895 and is headquartered in Bad Vilbel, Germany. STADA Arzneimittel Aktiengesellschaft is a subsidiary of Nidda Healthcare Holding GmbH. Receive STDAF News and Ratings via Email Sign-up to receive the latest news and ratings for STDAF and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Medicinals & botanicals Sub-IndustryN/A SectorMedical SymbolOTCMKTS:STDAF CUSIPN/A Webwww.stada.de Phone49-6101-6030 Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Price-To-Earnings Trailing P/E Ratio27.83 Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$2.61 billion Price / Sales2.24 Cash FlowN/A Price / CashN/A Book ValueN/A Price / BookN/A Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/A Miscellaneous EmployeesN/A Outstanding Shares62,340,000Market Cap$5,863.27 Stada Arzneimittel (OTCMKTS:STDAF) Frequently Asked Questions What is Stada Arzneimittel's stock symbol? Stada Arzneimittel trades on the OTCMKTS under the ticker symbol "STDAF." How were Stada Arzneimittel's earnings last quarter? Stada Arzneimittel (OTCMKTS:STDAF) announced its quarterly earnings results on Thursday, May, 3rd. The company reported $1.20 earnings per share (EPS) for the quarter. The firm had revenue of $685.72 million for the quarter. View Stada Arzneimittel's Earnings History. When is Stada Arzneimittel's next earnings date? Stada Arzneimittel is scheduled to release their next quarterly earnings announcement on Thursday, August, 2nd 2018. View Earnings Estimates for Stada Arzneimittel. What is the consensus analysts' recommendation for Stada Arzneimittel? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Stada Arzneimittel in the last year. There are currently 2 sell ratings for the stock, resulting in a consensus recommendation of "Sell." Who are some of Stada Arzneimittel's key competitors? Some companies that are related to Stada Arzneimittel include USANA Health Sciences (USNA), Chromadex (CDXC), Foamix Pharmaceuticals (FOMX), Mediwound (MDWD), Natural Alternatives International (NAII), Pharmacyte Biotech (PMCB), Mannatech (MTEX), China Jo-Jo Drugstores (CJJD), GLG Life Tech (GLGLF), Cyanotech (CYAN), ImmuDyne (IMMD), FitLife Brands (FTLF), Nutra Pharma (NPHC), Tauriga Sciences (TAUG) and Entia Biosciences (ERGO). Who are Stada Arzneimittel's key executives? Stada Arzneimittel's management team includes the folowing people: Dr. Claudio Albrecht, Chairman of the Exec. Board & CEO (Age 59)Mr. Mark Burgess Keatley MBA, MA, MPhil, CFO & Member of Exec. Board (Age 61)Dr. Barthold Piening, Chief Technical Operations Officer & Member of Exec. Board (Age 60)Ms. Leslie Isabelle Iltgen, VP of Investor RelationsMr. Sebastian Kramer-Bach, Exec. VP of Corp. Communication (Age 43) Has Stada Arzneimittel been receiving favorable news coverage? News headlines about STDAF stock have been trending somewhat positive on Sunday, Accern reports. The research group identifies positive and negative media coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Stada Arzneimittel earned a news impact score of 0.15 on Accern's scale. They also assigned news headlines about the company an impact score of 45.89 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the next several days. How do I buy shares of Stada Arzneimittel? Shares of STDAF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Stada Arzneimittel's stock price today? One share of STDAF stock can currently be purchased for approximately $94.05. How big of a company is Stada Arzneimittel? Stada Arzneimittel has a market capitalization of $5.86 billion and generates $2.61 billion in revenue each year. How can I contact Stada Arzneimittel? Stada Arzneimittel's mailing address is Stadastrasse 2-18, Bad Vilbel 2M, 61118. The company can be reached via phone at 49-6101-6030. MarketBeat Community Rating for Stada Arzneimittel (OTCMKTS STDAF)Community Ranking: 1.7 out of 5 ()Outperform Votes: 52 (Vote Outperform)Underperform Votes: 104 (Vote Underperform)Total Votes: 156MarketBeat's community ratings are surveys of what our community members think about Stada Arzneimittel and other stocks. Vote "Outperform" if you believe STDAF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe STDAF will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/22/2018 by MarketBeat.com StaffFeatured Article: What are Closed-End Mutual Funds?